Vicore Pharma Holding AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-477.47	-168.63	-310.94	-288.42	-296.48
Depreciation & Amortization	-	2.24	3.42	3.61	3.6
Loss (Gain) From Sale of Assets	-	-	-	2	-
Asset Writedown & Restructuring Costs	-	-	62.55	-	-
Other Operating Activities	61.01	3.28	6.03	3.83	0.64
Change in Accounts Receivable	-2.86	-35.6	-4.28	-1.6	-0.34
Change in Accounts Payable	44.89	33.77	-6.36	-19.34	27.41
Operating Cash Flow	-374.44	-164.95	-249.58	-299.92	-265.17
Sale (Purchase) of Intangibles	-	-	-	-3	-
Investment in Securities	-599.32	149.04	-144.46	77	-7
Other Investing Activities	-2.49	-	-	-	-
Investing Cash Flow	-601.81	149.04	-144.46	74	-7
Issuance of Common Stock	455.1	882.14	500.41	200	336
Other Financing Activities	-24.55	-48.08	-29.55	-12.96	-17.82
Financing Cash Flow	430.54	834.06	470.86	187.04	318.18
Foreign Exchange Rate Adjustments	-32.16	4.23	-	1.48	-0.43
Net Cash Flow	-577.85	822.38	76.82	-37.4	45.58
Free Cash Flow	-374.44	-164.95	-249.58	-299.92	-265.17
Free Cash Flow Margin	-9809.67%	-150.85%	-	-	-
Free Cash Flow Per Share	-1.56	-1.21	-2.58	-4.15	-3.81
Cash Interest Paid	-	0.01	0	0.01	0.01
Levered Free Cash Flow	-271.43	-111.57	-200.41	-195.17	-160.92
Unlevered Free Cash Flow	-239.96	-111.56	-200.41	-195.16	-160.92
Change in Working Capital	42.03	-1.84	-10.65	-20.94	27.07

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.